Have a feature idea you'd love to see implemented? Let us know!

ELTX Elicio Therapeutics Inc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: ELTX

Price (delayed)

$4.93

Market cap

$53.2M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.95

Enterprise value

$51.92M

Highlights
The quick ratio has soared by 110% YoY
Elicio Therapeutics's EPS has soared by 86% YoY
The net income has declined by 42% year-on-year and by 21% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Peers: OLMA OMER OMGA ONCT

Key stats

What are the main financial stats of ELTX
Market
Shares outstanding
10.79M
Market cap
$53.2M
Enterprise value
$51.92M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$46.62M
EBITDA
-$45.46M
Free cash flow
-$38.26M
Per share
EPS
-$6.95
Free cash flow per share
-$2.82
Book value per share
-$1.76
Revenue per share
$0
TBVPS
$2.83
Balance sheet
Total assets
$38.39M
Total liabilities
$57.37M
Debt
$26.05M
Equity
-$18.99M
Working capital
$21.63M
Liquidity
Debt to equity
-1.37
Current ratio
3.4
Quick ratio
3.03
Net debt/EBITDA
0.03
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-177.2%
Return on equity
N/A
Return on invested capital
-299.7%
Return on capital employed
-158.7%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ELTX stock price

How has the Elicio Therapeutics stock price performed over time
Intraday
-3.71%
1 week
-10.04%
1 month
3.14%
1 year
-11.33%
YTD
-40.89%
QTD
-1.99%

Financial performance

How have Elicio Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$40.9M
Net income
-$46.84M
Gross margin
N/A
Net margin
N/A
The net income has declined by 42% year-on-year and by 21% since the previous quarter
The operating income has declined by 27% year-on-year

Growth

What is Elicio Therapeutics's growth rate over time

Valuation

What is Elicio Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Elicio Therapeutics's EPS has soared by 86% YoY

Efficiency

How efficient is Elicio Therapeutics business performance
The company's return on assets has shrunk by 79% YoY and by 13% QoQ
ELTX's return on invested capital is down by 23% year-on-year but it is up by 14% since the previous quarter

Dividends

What is ELTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ELTX.

Financial health

How did Elicio Therapeutics financials performed over time
The total assets is 33% smaller than the total liabilities
The total assets has surged by 144% since the previous quarter and by 24% year-on-year
The quick ratio has soared by 110% YoY
Elicio Therapeutics's debt to equity has soared by 65% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.